Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cytokinetics (NQ: CYTK ) 52.34 -0.29 (-0.55%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cytokinetics < Previous 1 2 3 4 5 6 7 Next > Analysts Think There's Still Time to Get in on Edgewise, Up 332% September 25, 2024 Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? Via MarketBeat Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip September 19, 2024 Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. Via Investor's Business Daily Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study September 09, 2024 Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerability, and dose-linearity. Phase 2 trial expected to start Q4 2024. Via Benzinga CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? July 11, 2024 CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. Via Investor's Business Daily Peering Into Cytokinetics's Recent Short Interest June 07, 2024 Via Benzinga (CYTK) - Analyzing Cytokinetics's Short Interest May 01, 2024 Via Benzinga $100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today April 03, 2024 Via Benzinga 7 Biotech Stocks to Boost Your Portfolio to Peak Health June 26, 2024 With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. Via InvestorPlace June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge June 05, 2024 Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. Via InvestorPlace Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views May 23, 2024 Via Benzinga Topics Earnings Stocks Exposures Financial US Equities Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe May 23, 2024 Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. Via Benzinga 8 Health Care Stocks Whale Activity In Today's Session May 23, 2024 Via Benzinga 2 Incredible Growth Stocks to Buy Right Now March 20, 2024 These two biotech stocks could be big winners in the years ahead. Via The Motley Fool Stocks Mixed Amid Flood Of Economic Data May 23, 2024 The Nasdaq is up triple digits midday, trading at fresh record highs thanks to Nvidia's post-earnings pop. Via Talk Markets 12 Health Care Stocks Moving In Thursday's Intraday Session May 23, 2024 Via Benzinga Gold Falls Sharply; US Composite PMI Surges In May May 23, 2024 Via Benzinga Why Cytokinetics (CYTK) Shares Are Falling May 23, 2024 Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares. Via Benzinga Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket May 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 23, 2024 Via Benzinga NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday May 23, 2024 Via Benzinga VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session May 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session May 22, 2024 Via Benzinga Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline May 22, 2024 From Royalty Pharma plc; Cytokinetics Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session May 17, 2024 Via Benzinga Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day May 13, 2024 The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. Via Investor's Business Daily CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare May 07, 2024 Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. Via InvestorPlace 3 Biotech Stocks to Buy on the Dip: April 2024 April 26, 2024 With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. Via InvestorPlace 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.